In This Section
Advertisement
SNM Submits Comments to FDA on Standards for Clinical Imaging Endpoints
January 10, 2012
On October 18, 2011, SNM submitted comments on draft guidance for Industry on Standards for Clinical Trial Imaging Endpoints.
SNM offers several recommendations in order to better the imaging standards and procedures.
The SNM applauds the efforts of the FDA to standardize imaging procedures when an imaging endpoint is used in a clinical trial of a therapeutic or biologic drug product. This guidance will prove valuable for the sponsors of trials and provide areas for discussion with imaging professionals.
To view the comment letter, please click on the attached document.